-
Nanomedicine Could Improve Patient Outcomes and Reduce Healthcare Costs
Nanomaterials have been increasingly recognized as a promising component of the future of biotechnology and biomedicine. These nanoparticles are measured on the molecular scale, and their extra-small (billionths of a meter) size lends itself to better drug delivery methods and more personalized treatment regimens. The …
Read More -
Mississippi, You’re On My Mind
New research by pharmacy benefit manager Express Scripts has found that the “U.S. wasted $418 billion in 2012 based on bad medication-related decisions, and the impact was most deeply felt in those states that could least afford it.” The Express Scripts analysis looked at pharmacy-related decisions …
Read More -
NCPA Endorses Bill to Increase Medicare Drug Costs
With Medicare spending representing a massive and growing part of federal deficits, why would anyone want to increase Medicare costs? But that’s just what new legislation backed by the National Community Pharmacists Association would do. The bill, S. 867, introduced on May 6, 2013, by Senators …
Read More -
Health Care Fraud Costs Everyone
Without a doubt, our nation’s health care system faces an array of challenges related to quality, affordability, and access. Given the breadth of our challenges, it makes the prevalence of fraud, waste, and abuse in our system that much more frustrating and galling. Depending on …
Read More -
New Report Details Potential Medicaid Savings from Using PBM Tools
In addition to offering significant savings for private health insurers, pharmacy benefit management (PBM) tools could save the Federal government and state governments $74.4 billion in Medicaid costs over ten years according to a new report by the Menges Group prepared for the Pharmaceutical Care …
Read More -
Diabetes Patients May See Improved Outcomes with New Weekly Injection
Diabetes is one of the most common chronic diseases of our generation, affecting about 25.8 million Americans and 371 million people worldwide. Type 2 diabetes accounts for between 90 and 95% of all diabetes cases. For international as well as domestic healthcare agencies, designing an …
Read More -
FDA Blocks U.S. Introduction of Generic OxyContin
This past December, Canada’s Health Ministry approved the manufacture and sale of generic oxycodone in its originally patented non-abuse resistant formulation. This year, it was the FDA’s turn to consider the issue, with Purdue Pharma’s original non-abuse resistant formulation patent of OxyContin expiring April 16th. …
Read More -
Ignore the Fine Print, Just Sign Here Please…
Every so often, we come across an innocuous news article that highlights a divergence between Washington lobbying rhetoric and marketplace practices. Recently, the Wall Street Journal ran a front-page article about Procter & Gamble moving to extend its payment terms with suppliers from an average …
Read More -
Pharmaceutical Companies Playing on Safety Rules to Impede Cost-Saving Generics
In a recent post, we talked about how pharmaceutical companies use “evergreen” techniques to work around the expiration of patents and extend profitable exclusivity periods for branded drugs. Now the New York Times has revealed another set of techniques in what pharmaceutical companies euphemistically call …
Read More -
New Developments on Improving Health and Reducing Costs through Vaccines
As the Affordable Care Act celebrates its third anniversary, the Department of Health and Human Services (HHS) has announced the extension of preventive services coverage to approximately 105 million Americans, including 34 million Medicare beneficiaries. Currently, the U. S. spends close to 18% of the …
Read More